Literature DB >> 17714037

Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report.

Jason E Faris1, Allan F Moore, Gilbert H Daniels.   

Abstract

Numerous drugs have been associated with destructive thyroiditis (subacute thyroiditis). Sunitinib, a tyrosine kinase inhibitor employed in renal cell carcinoma and gastrointestinal stromal tumors, has recently been linked to destructive thyroiditis with resultant hypothyroidism. We report a patient with transient overt thyrotoxicosis followed by hypothyroidism, apparently related to sunitinib therapy.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17714037     DOI： 10.1089/thy.2007.0104

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


  9 in total

Review 1.  Thyroid dysfunction from antineoplastic agents.

Authors:  Ole-Petter Riksfjord Hamnvik; P Reed Larsen; Ellen Marqusee
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

2.  Sunitinib-induced thyrotoxicosis.

Authors:  D Piñar; E Boix; J A Meana; J Herrero
Journal:  J Endocrinol Invest       Date:  2009-07-28       Impact factor: 4.256

3.  Thyroid dysfunction in patients treated with sunitinib or sorafenib.

Authors:  Julia Clemons; Dexiang Gao; Mary Naam; Kathryn Breaker; David Garfield; Thomas W Flaig
Journal:  Clin Genitourin Cancer       Date:  2012-09-25       Impact factor: 2.872

Review 4.  Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature.

Authors:  Ph Kaldrymides; I Kostoglou-Athanassiou; A Gkountouvas; E Veniou; N Ziras
Journal:  Endocrine       Date:  2010-01-06       Impact factor: 3.633

Review 5.  Endocrine side effects of broad-acting kinase inhibitors.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

6.  Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma.

Authors:  Sahzene Yavuz; Andrea B Apolo; Shivaani Kummar; Jaydira del Rivero; Ravi A Madan; Thomas Shawker; James Reynolds; Francesco S Celi
Journal:  Thyroid       Date:  2014-06-05       Impact factor: 6.568

Review 7.  Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.

Authors:  Roger B Cohen; Stéphane Oudard
Journal:  Invest New Drugs       Date:  2012-02-12       Impact factor: 3.850

Review 8.  Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment.

Authors:  Hala Ahmadieh; Ibrahim Salti
Journal:  Biomed Res Int       Date:  2013-10-27       Impact factor: 3.411

9.  Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors.

Authors:  R Rodia; F Pani; G Caocci; G La Nasa; M P Simula; O Mulas; F Velluzzi; A Loviselli; S Mariotti; F Boi
Journal:  J Endocrinol Invest       Date:  2021-07-20       Impact factor: 4.256
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.